Top

Published in:

01-03-2018 | Original Paper

Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease

Authors: Insa E. Emrich, Adam M. Zawada, Jens Martens-Lobenhoffer, Danilo Fliser, Stefan Wagenpfeil, Gunnar H. Heine, Stefanie M. Bode-Böger

Published in: Clinical Research in Cardiology | Issue 3/2018

Abstract

Background

Chronic kidney disease (CKD) is associated with increased risk of renal and cardiovascular events. It has been claimed that endogenous methylarginines, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), are contributing factors. However, earlier studies were partly contradictory and mainly focused on prevalent dialysis patients. Moreover, the potential contribution of degradation products, such as acetylated ADMA and SDMA (AcADMA and AcSDMA) and other methylarginines including L-N^G-monomethylarginine (LNMMA) remains unknown. To better understand their potential pathophysiological contribution to renal and cardiovascular events, we aimed to provide a comprehensive analysis of methylarginines in a cohort of patients with non-dialysis CKD.

Methods

Blood samples of 528 patients with CKD KDIGO G2 to G4 were obtained from the CARE FOR HOMe study. Baseline plasma levels of ADMA, SDMA, AcADMA, AcSDMA, and LNMMA were measured by liquid chromatography—tandem mass spectrometry. All patients were followed annually for CKD progression and for incident atherosclerotic cardiovascular events.

Results

During 5.1 ± 2.1 years follow-up, 80 patients displayed CKD progression and 145 patients developed incident atherosclerotic cardiovascular events. In univariate Cox regression analyses, elevated plasma levels of all five metabolites were associated with both CKD progression and atherosclerotic cardiovascular disease. However, adjustment for confounders attenuated the prognostic implications of ADMA, LNMMA, AcADMA and AcSDMA. In contrast, patients in the highest tertile of plasma SDMA remained at highest risk for CKD progression and incident atherosclerotic cardiovascular events in fully adjusted Cox regression analyses.

Conclusion

Our results underline a potential pathophysiological role of SDMA in CKD progression and atherosclerotic cardiovascular disease among non-dialysis CKD patients. SDMA predicts CKD progression and future atherosclerotic cardiovascular events more consistently than other methylarginines. Future experimental and clinical studies should therefore focus upon SDMA rather than upon ADMA.

Available only for authorised users

(IEE and GHH)

Go AS, Chertow GM, Fan D et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296–1305CrossRefPubMed

Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382(9889):339–352CrossRefPubMed

Hallan SI, Coresh J, Astor BC et al (2006) International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 17(8):2275–2284CrossRefPubMed

Stahli BE, Gebhard C, Gick M et al. (2017) Outcomes of patients with periprocedural atrial fibrillation undergoing percutaneous coronary intervention for chronic total occlusion. Clin Res Cardiol. https://doi.org/10.1007/s00392-017-1148-4

Fu M, Ahrenmark U, Berglund S et al. (2017) Adherence to optimal heart rate control in heart failure with reduced ejection fraction: insight from a survey of heart rate in heart failure in Sweden (HR-HF study). Clin Res Cardiol. https://doi.org/10.1007/s00392-017-1146-6 PubMedPubMedCentral

O’Neal WT, Efird JT, Kamel H et al (2015) The association of the QT interval with atrial fibrillation and stroke: the Multi-Ethnic Study of Atherosclerosis. Clin Res Cardiol 104(9):743–750CrossRefPubMedPubMedCentral

Laursen PN, Holmvang L, Kelbaek H et al (2017) Drop-out from cardiovascular magnetic resonance in a randomized controlled trial of ST-elevation myocardial infarction does not cause selection bias on endpoints. Clin Res Cardiol 106(7):525–532CrossRefPubMed

Lee SY, Hong MK, Shin DH et al (2017) Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. Clin Res Cardiol 106(3):165–173CrossRefPubMed

Custodis F, Roggenbuck U, Lehmann N et al (2016) Resting heart rate is an independent predictor of all-cause mortality in the middle aged general population. Clin Res Cardiol 105(7):601–612CrossRefPubMed

10.

Zeus T, Ketterer U, Leuf D et al (2016) Safety of percutaneous coronary intervention in patients with acute ischemic stroke/transient ischemic attack and acute coronary syndrome. Clin Res Cardiol 105(4):356–363CrossRefPubMed

11.

Meyer T, Herrrmann-Lingen C, Chavanon ML et al (2015) Higher plasma levels of MR-pro-atrial natriuretic peptide are linked to less anxiety: results from the observational DIAST-CHF study. Clin Res Cardiol 104(7):574–581CrossRefPubMed

12.

Levey AS, Atkins R, Coresh J et al (2007) Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 72(3):247–259CrossRefPubMed

13.

Kielstein JT, Zoccali C (2005) Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 46(2):186–202CrossRefPubMed

14.

Schepers E, Speer T, Bode-Boger SM et al (2014) Dimethylarginines ADMA and SDMA: the real water-soluble small toxins? Semin Nephrol 34(2):97–105CrossRefPubMed

15.

Willeit P, Freitag DF, Laukkanen JA et al (2015) Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc 4(6):e001833CrossRefPubMedPubMedCentral

16.

Vallance P, Leone A, Calver A et al (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. The Lancet 339(8793):572–575CrossRef

17.

Yilmaz MI, Saglam M, Caglar K et al (2006) The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47(1):42–50CrossRefPubMed

18.

Boger RH, Bode-Boger SM, Thiele W et al (1997) Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95(8):2068–2074CrossRefPubMed

19.

Bode-Boger SM, Scalera F, Kielstein JT et al (2006) Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 17(4):1128–1134CrossRefPubMed

20.

Kielstein JT, Bode-Boger SM, Frolich JC et al (2003) Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 107(14):1891–1895CrossRefPubMed

21.

Fliser D, Kronenberg F, Kielstein JT et al (2005) Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 16(8):2456–2461CrossRefPubMed

22.

Ravani P, Tripepi G, Malberti F et al (2005) Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16(8):2449–2455CrossRefPubMed

23.

Hanai K, Babazono T, Nyumura I et al (2009) Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transpl 24(6):1884–1888CrossRef

24.

Kielstein JT, Boger RH, Bode-Boger SM et al (2002) Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13(1):170–176PubMed

25.

Zoccali C, Bode-Boger S, Mallamaci F et al (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358(9299):2113–2117CrossRefPubMed

26.

Shafi T, Hostetter TH, Meyer TW et al. Serum asymmetric and symmetric dimethylarginine and morbidity and mortality in hemodialysis patients. Am J Kidney Dis 2017

27.

Schlesinger S, Sonntag SR, Lieb W et al (2016) Asymmetric and symmetric dimethylarginine as risk markers for total mortality and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. PLoS One 11(11):e0165811CrossRefPubMedPubMedCentral

28.

Busch M, Fleck C, Wolf G et al (2006) Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease—possible candidates for paradoxical epidemiology? Amino Acids 30(3):225–232CrossRefPubMed

29.

Tripepi G, Mattace Raso F, Sijbrands E et al (2011) Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol 6(7):1714–1721CrossRefPubMed

30.

Drew DA, Tighiouart H, Scott T et al (2014) Asymmetric dimethylarginine, race, and mortality in hemodialysis patients. Clin J Am Soc Nephrol 9(8):1426–1433CrossRefPubMedPubMedCentral

31.

Aucella F, Maas R, Vigilante M et al (2009) Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study. Atherosclerosis 207(2):541–545CrossRefPubMed

32.

Mendes Ribeiro AC, Roberts NB, Lane C et al (1996) Accumulation of the endogenous l-arginine analogue NG-monomethyl-l-arginine in human end-stage renal failure patients on regular haemodialysis. Exp Physiol 81(3):475–481CrossRefPubMed

33.

Torremans A, Marescau B, Vanholder R et al (2003) The low nanomolar levels of N G-monomethylarginine in serum and urine of patients with chronic renal insufficiency are not significantly different from control levels. Amino Acids 24(4):375–381CrossRefPubMed

34.

Caplin B, Wang Z, Slaviero A et al (2012) Alanine-glyoxylate aminotransferase-2 metabolizes endogenous methylarginines, regulates NO, and controls blood pressure. Arterioscler Thromb Vasc Biol 32(12):2892–2900CrossRefPubMed

35.

Martens-Lobenhoffer J, Bode-Boger SM (2015) Amino acid N-acetylation: metabolic elimination of symmetric dimethylarginine as symmetric N(alpha)-acetyldimethylarginine, determined in human plasma and urine by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 975:59–64CrossRefPubMed

36.

Martens-Lobenhoffer J, Rodionov RN, Bode-Boger SM (2014) Determination of asymmetric Nalpha-acetyldimethylarginine in humans: a phase II metabolite of asymmetric dimethylarginine. Anal Biochem 452:25–30CrossRefPubMed

37.

Rodionov RN, Martens-Lobenhoffer J, Brilloff S et al (2016) Acetylation of asymmetric and symmetric dimethylarginine: an undercharacterized pathway of metabolism of endogenous methylarginines. Nephrol Dial Transpl 31(1):57–63CrossRef

38.

Grun OS, Herath E, Weihrauch A et al (2012) Does the measurement of the difference of resistive indexes in spleen and kidney allow a selective assessment of chronic kidney injury? Radiology 264(3):894–902CrossRefPubMed

39.

Wolf A, Zalpour C, Theilmeier G et al (1997) Dietary l-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 29(3):479–485CrossRefPubMed

40.

Boger RH, Bode-Boger SM, Tsao PS et al (2000) An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 36(7):2287–2295CrossRefPubMed

41.

Boger RH, Bode-Boger SM, Kienke S et al (1998) Dietary l-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. Atherosclerosis 136(1):67–77CrossRefPubMed

42.

Zhou YM, Lan X, Guo HB et al (2014) Rho/ROCK signal cascade mediates asymmetric dimethylarginine-induced vascular smooth muscle cells migration and phenotype change. Biomed Res Int 2014:683707PubMedPubMedCentral

43.

Boger RH, Bode-Boger SM, Mugge A et al (1995) Supplementation of hypercholesterolaemic rabbits with l-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 117(2):273–284CrossRefPubMed

44.

Hogg N, Kalyanaraman B, Joseph J et al (1993) Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 334(2):170–174CrossRefPubMed

45.

Closs EI, Basha FZ, Habermeier A et al (1997) Interference of l-arginine analogues with l-arginine transport mediated by the y + carrier hCAT-2B. Nitric Oxide 1(1):65–73CrossRefPubMed

46.

Zewinger S, Kleber ME, Rohrer L et al. (2017) Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease. Eur Heart J 38(20):1597–1607CrossRefPubMed

47.

Speer T, Rohrer L, Blyszczuk P et al (2013) Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 38(4):754–768CrossRefPubMed

48.

Schwedhelm E, Boger RH (2011) The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol 7(5):275–285CrossRefPubMed

49.

Kielstein JT, Salpeter SR, Bode-Boeger SM et al (2006) Symmetric dimethylarginine (SDMA) as endogenous marker of renal function–a meta-analysis. Nephrol Dial Transpl 21(9):2446–2451CrossRef

50.

Lu TM, Chung MY, Lin CC et al (2011) Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease. Clin J Am Soc Nephrol 6(7):1566–1572CrossRefPubMed

51.

Young JM, Terrin N, Wang X et al (2009) Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol 4(6):1115–1120CrossRefPubMedPubMedCentral

52.

Hov GG, Aasarod KI, Sagen E et al (2015) Arginine, dimethylated arginine and homoarginine in relation to cardiovascular risk in patients with moderate chronic kidney disease. Clin Biochem 48(10–11):646–651CrossRefPubMed

53.

Frenay AR, van den Berg E, de Borst MH et al (2015) Plasma ADMA associates with all-cause mortality in renal transplant recipients. Amino Acids 47(9):1941–1949CrossRefPubMedPubMedCentral

54.

Abedini S, Meinitzer A, Holme I et al (2010) Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int 77(1):44–50CrossRefPubMed

55.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1–150

56.

Siegerink B, Maas R, Vossen CY et al (2013) Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. Clin Res Cardiol 102(3):193–202CrossRefPubMed

Title: Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease
Authors: Insa E. Emrich
Adam M. Zawada
Jens Martens-Lobenhoffer
Danilo Fliser
Stefan Wagenpfeil
Gunnar H. Heine
Stefanie M. Bode-Böger
Publication date: 01-03-2018
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 3/2018
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-017-1172-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2018

Stratified prevention: opportunities and limitations. Report on the 1st interdisciplinary cardiovascular workshop in Augsburg

Outcomes after percutaneous coronary intervention for chronic total occlusion according to baseline renal function

Prognostic impact of atrial fibrillation in cardiogenic shock complicating acute myocardial infarction: a substudy of the IABP-SHOCK II trial

Prognostic value of preprocedural 6-min walk test in patients undergoing transcatheter mitral valve repair—insights from the German transcatheter mitral valve interventions registry

Influence of hydrostatic pressure on intracoronary indices of stenosis severity in vivo

Electrical cardioversion of patients with implanted pacemaker or cardioverter–defibrillator: results of a survey of german centers and systematic review of the literature

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page